Recorded Webinar – Development of a new Antibody-drug Conjugate Diafiltration Process and Use of a Novel TFF Capsule

Pellicon® Capsules

Recorded: June 14, 2017

Speaker: Eric Lacoste, Head of ADC Process Development Team at Sanofi

Title: Development of a new Antibody-drug Conjugate Diafiltration Process and Use of a Novel TFF Capsule

Lonza
ADC Bio
MabPlex
 

Abstract: This webinar highlights Tangential Flow Filtration (TFF) case studies during Antibody Drug Conjugate (ADC) process development within Sanofi and provides preliminary results on a novel single-use TFF capsule.

ADC therapies have been a booming field within the last decade, and remain a key possibility for Paul Ehrlich’s vision of a magic bullet concept for personalized medicine. However, ADC process development and manufacturing remain very challenging due to the intrinsic complexity of these drug entities.
The generic ADC process is composed of at least three steps: chemical reactions in aqueous buffer (including some organic solvent); purification and formulation steps. This webinar will highlight TFF case studies during ADC purification process development within Sanofi, and will provide preliminary results using a novel single-use TFF capsule. This new device is designed to replace standard TFF cassettes, providing the same level of performance while offering improved process containment.

In this webinar, you will learn:

  • TFF process development
  • Implementation of a TFF capsule instead of cassette